Castle Biosciences (CSTL) Capital Leases (2023 - 2026)

Castle Biosciences has reported Capital Leases for 4 years, with the latest figure at $264000.0 in Q2 2026.

• Quarterly Capital Leases fell 27.47% year-over-year to $264000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $264000.0 (down 27.47% YoY) and the FY2025 annual result came in at $314000.0, up 0.96% from the prior year.
• Capital Leases fell to $264000.0 in Q2 2026 per CSTL's latest filing, from $288000.0 in the prior quarter.
• Over five years, Capital Leases peaked at $364000.0 in Q2 2025 and troughed at $25000.0 in Q4 2023.
• A 4-year average of $283400.0 and a median of $311500.0 in 2024 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2024 and 2026: Capital Leases surged 1144.0% in 2024, then dropped 27.47% in 2026.
• Over 4 years, Capital Leases stood at $25000.0 in 2023, then soared by 1144.0% to $311000.0 in 2024, then rose by 0.96% to $314000.0 in 2025, then dropped by 15.92% to $264000.0 in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $264000.0, $288000.0, and $314000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.